Every life sciences company knows that patient safety is non negotiable, but the way safety is managed—and the value ...
Q4 revenue is expected at $41.55 million versus $14.7 million in Q3, while EPS is projected at approximately negative $0.20 GAAP. Over the past eight quarters, ASTS delivered only two EPS beats versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results